Bringing the fundamentals into focus…
Back to Zenas BioPharma, Inc.
How Zenas BioPharma, Inc. stacks up
ZBIO · against 454 other Healthcare companies listed in US-listed
Growth
4/ 100
Near the bottom of its peers.
Ranked #431 of 455 · scores higher than 4% of peers
Bars: peers in each 10-point band of the growth score44 peers with a growth score of 0–9, including ZBIO · Click a bar to see the companies
Why growth scores 4?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth and earnings per share growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 99% of peers. Revenue growth: -93.3% vs peer median 6.1%
- The loss per share widened. Earnings per share growth: — vs peer median 9.8%
- 3-year revenue growth is not reported, so it is left out of the score.
Metric by metric
Position: dot = ZBIO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ZBIO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 475 reported | -93.3% | 11.0% | 4% | 33% | |
| Earnings per share growthHigher is better · 171 reported | Not reported | 21.2% | — | — | 33% |
| 3-year revenue growthHigher is better · 433 reported | Not reported | 11.0% | — | — | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around ZBIO| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 433M USD | 99 | 81 | |
| 2 | 8.8B USD | 99 | 31 | |
| 2 | 90M USD | 99 | 27 | |
| 431 | 320M USD | 4 | 44 | |
| 431 | 7.8B USD | 4 | 30 | |
| 431 | 223M USD | 4 | 34 | |
| 431 | 184M USD | 4 | 33 | |
| 431 | 1.8B USD | 4 | 23 | |
| 436 | 271M USD | 3 | 14 | |
| 436 | 475M USD | 3 | 22 | |
| 436 | 888M USD | 3 | 25 | |
| 436 | 1.1B USD | 3 | 26 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score